Biomarker ID | 1610 |
PMID | 31045265 |
Year | 2019 |
Biomarker | mir-145 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathway include: MicroRNAs in cancer; Heart Development; miRNAs involved in DNA damage response; SRF and miRs in Smooth Muscle Differentiation and Proliferation |
Experiment | Gleason Score Upgradation Vs No Upgradation |
Type of Biomarker | Prognostic |
Cohort | 45 patients with prostate cancer were included for this study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.03 |
Method Used | RT-PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |